We read with interest the Editorial [1] and the two studies recently published on this Journal [2, 3] regarding the hypothalamic-pituitary-adrenal axis disruption in type 2 diabetes mellitus (T2D) and its consequences on the glycometabolic control.
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We agree with Raff and Magill that it would be prudent to screen for a condition of subtle hypercortisolism all patients with poorly controlled T2D. Beside this consideration, we would like to focus on the fact that, in addition to the metabolic control, the degree of cortisol secretion in T2D (even within the normal range) might be associated with the T2D related bone damage. Interestingly, there are interrelations and similarities between T2D and the condition of hypercortisolism not only regarding the pathogenesis of the glucose metabolism alteration in both conditions, but possibly also regarding the pathogenesis of the bone tissue alterations.
Firstly, osteoporosis in T2D is characterized by a low bone turnover with a normal/decreased bone resorption and decreased bone apposition, partially due to the inhibition of the Wnt/β-catenin signaling. Indeed, this pathway is a critical regulator of osteoblastogenesis and in the T2D related osteoporosis its inhibition may lead to a preferential differentiation of the mesenchymal cells toward adipocytes than toward osteoblasts. Similarly, in the glucocorticoid (GC) induced osteoporosis (GIO) the osteoblast differentiation is inhibited, due to a mesenchymal cells shift toward cells of the adipocytic lineage instead of toward osteoblasts. In addition, the GC excess decrease osteoblastic function and promote osteoblast and osteocyte apoptosis. This latter effect induces bone microarchitectural alterations, reducing bone quality. During the initial period of GC excess bone resorption is increased due to the enhanced levels of the receptor activator of nuclear factor kappa-B ligand and the decreased osteoprotegerin production in osteoblasts. As the GC exposure continues, bone remodeling decreases and the inhibition of bone apposition becomes the main pathogenetic mechanism of skeletal damage. Finally, the occurrence of an enhanced porosity of the cortical bone has been described as a further mechanism increasing the fracture risk in GIO.
Secondly, in T2D patients, the diabetic chronic complications and the scarce glycometabolic control seem to be associated with the hip fracture risk. Indeed, the cortical porosity and the fracture risk are particularly increased in patients with T2D chronic complications. Interestingly, these latter patients have also higher cortisol levels than patients with not complicated T2D.
Thirdly, recent data show that, as compared with not diabetic subjects, in T2D patients (even in those with good metabolic control) the cortisol secretion is in the upper limit of the normal range, bone turnover is reduced and the vertebral fractures prevalence is associated with both cortisol secretion and the N363S sensitizing variant of the glucocorticoid receptor (GR) gene. Interestingly, the GR gene polymorphisms have been found to potentially influence both glycometabolic control and bone function. Indeed, the N363S polymorphism and the Bcl1 intronic mutation in the GR gene seem to increase GC sensitivity. These polymorphic variants (in heterozygosis for N363S and in homozygosis for Bcl1) seem to be associated with a worse metabolic profile and a decreased spinal and trochanteric bone density. However, an increased sensitivity of the GR should lower the circulating cortisol levels, so that their action at the GR should be correspondingly reduced. However, the GC sensitivity of bone may be increased in the conditions of endogenous or exogenous hypercortisolism.
Finally, an agent inhibiting the 11-βhydroxysteroid dehydrogenase type 11 (11HSD1) activity, named INCB13739, has been found to ameliorate the glycometabolic control, without negatively affecting the basal cortisol homeostasis and androgens levels. Furthermore, animal and in vitro studies suggested the potential role of a 11HSD1 inhibitor in stimulating osteoblast differentiation.
These considerations may be of clinical interest. Indeed, if osteoporosis in T2D was related, at least partially, to the degree cortisol secretion and/or sensitivity, the treatment with an 11HSD1 inhibitor could improve diabetic control and reduce the fracture risk at the same time.
However, since the majority of the available studies are cross-sectional, it is still unclear if the alterations of the cortisol secretion may really influence the control of T2D. Furthermore, osteoporosis is a multifactorial disease and, therefore, the possible causative effects of the disrupted cortisol secretion on bone health is difficult to be understood. Finally, even if the altered cortisol secretion may contribute to the pathogenesis of the osteoporosis in T2D, it is to be determined whether lowering cortisol secretion rate is more beneficial for bone than a strict glycometabolic control. Therefore, the suggestion of using 11HSD inhibitors as a potential therapy for T2D related osteoporosis is, at the moment, entirely speculative.
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